New Options in Breast Cancer - Clinical Scenarios
WebcastFaculty
OVERVIEW
New Options in Breast Cancer - Clinical Scenarios is organized by prIME Oncology and will be held during May 22, 2017 - May 22, 2018..
The target audience for this medical event is specifically designed for community oncologists, nurse practitioners, physicians’ assistants, nurses, and other healthcare professionals who manage and treat patients with breast cancer. This CME Conference has been approved for a maximum of 0.5 AMA PRA Category 1 Credits.
These interactive clinical scenarios allow participants to choose treatment, compare their answers to those of their peers, and read commentary from expert faculty, providing healthcare professionals with guidance on the management of patients with breast cancer.
Conference Objectives are :
After successful completion of this educational activity, participants should be able to:
Physicians:
• Incorporate emerging efficacy and safety data from clinical trials of CDK4/6 inhibitory therapies into individualized treatment planning
• Identify strategies for the mitigation and management of adverse events associated with emerging CDK4/6 inhibitory therapies in the management of metastatic breast cancer
Nurses:
• Evaluate current and emerging strategies for managing ER+ breast cancer
• Identify the most common treatment-associated side effects, and select appropriate strategies for prevention, recognition, and management of these events
Additional details will be posted as soon as they are available.
The target audience for this medical event is specifically designed for community oncologists, nurse practitioners, physicians’ assistants, nurses, and other healthcare professionals who manage and treat patients with breast cancer. This CME Conference has been approved for a maximum of 0.5 AMA PRA Category 1 Credits.
These interactive clinical scenarios allow participants to choose treatment, compare their answers to those of their peers, and read commentary from expert faculty, providing healthcare professionals with guidance on the management of patients with breast cancer.
Conference Objectives are :
After successful completion of this educational activity, participants should be able to:
Physicians:
• Incorporate emerging efficacy and safety data from clinical trials of CDK4/6 inhibitory therapies into individualized treatment planning
• Identify strategies for the mitigation and management of adverse events associated with emerging CDK4/6 inhibitory therapies in the management of metastatic breast cancer
Nurses:
• Evaluate current and emerging strategies for managing ER+ breast cancer
• Identify the most common treatment-associated side effects, and select appropriate strategies for prevention, recognition, and management of these events
Additional details will be posted as soon as they are available.
SPECIALITIES
Oncology
Quick Links